http://WWW.CANCERINFO.IN
http://WWW.CANCERINFO.IN

Checking delivery availability...

background-sm
Search
3

Updates found with 'positive'

Page  1 1

Updates found with 'positive'

Genetic testing for breast and ovarian Cancer1)what is genetic testing?Answer:-Genetic make up of an individual is like a house map.Any abnormality in the house map will lead to a faulty construction of the house, similarly any abnormality in the gene may lead to disease. This abnormality in genes is referred to as mutations.There are tests which can find out these specific mutations.2) Are there genes identified which increase risk of breast and ovarian cancer?Answer:There are several genes but the most well known and commonly tested genes are BRCA1 and BRCA2.several other candidate genes have been identified and research in this area is ongoing.3)Who should have genetic test for breast and ovarian cancer?Answer:we offer genetic test for women who have strong family history of breast or ovarian cancer. which is as follows:-a) two or more relatives with breast or ovarian cancer; especially if diagnosed at age <50 years.b) close family member with cancer of both breast or breast and ovarian cancer in same individual.c) if you have family members from different generation with breast or ovarian cancer.note: STRONG FAMILY HISTORY DOES NOT MEAN YOU HAVE ABNORMAL GENE AND INFACT MOST WOMEN WITH FAMILY HISTORY DO NOT HAVE THESE MUTATIONS.it is important to consult your doctor who will work out your individual risk prior to ordering these tests and discuss the pros and cons of the test as well.Q how can we lower chances of getting cancer if one turn out BRCA positive?Answer:a) getting screened for breast lump using MRI or mammogram as advised by your doctorb) breast and ovaries removal after completing Your family.c) there are tablets available as wellwhich option will be best for an individual is decided on case to case basis by treating doctor and individual preference.
Send Enquiry
Read More
Maintenance with PARP inhibitor is the way forward in ovarian cancer:Median PFS in platinum sensitive relapse carcinoma ovary is approximately 10 months.20% of high grade serous carcinoma ovary have somatic or germline mutation in BRCA gene.Single stranded DNA breaks are repaired Base excision repair pathways of which PARP ( poly ADP ribose polymerase) enzymes are one of the key members.In presence of PARP inhibitors these single stranded breaks are converted into double stranded breaks and the repair of these double stranded breaks require intact Homologous recombination repair pathway. BRCA proteins are integral part of these Homologous recombination pathway.In presence of BRCA gene muatation the double stranded breaks produced in presence of PARP inhibitor bring about lethal damage to the cancer cells.Olaparib is the most extensively studied PARP inhibitor and it is approved in BRCA mutation positive relapse high grade carcinoma ovary as single agent after 3 or more lines of chemotherapy. Also Olaparib has been approved as maintenance in both BRCA mutated and wild type patients in relapse platinum sensitive high grade carcinoma ovary who attain CR or PR to last line platinum doublet.The reported PFS in this setting is around 18 months in BRCA mutated (SOLO-2 trial-using tablet olaparib 300mg twice daily) v/s 9 months in BRCA wild type based on STUDY- 19 Trial (Capsule Olaparib 400mg twice daily).It is important to note that about 15% patients remain progression free at 5 years in study-19 trial on Olaparib ( these long term progression free survival benefited both BRCA wild type and BRCA mutated subgroup) .Niraparib based on the result of NOVA trial (300 mg once daily) got approval in maintenance for both BRCA mutated and wild type patients in relapse platinum sensitive high grade carcinoma ovary who attain CR or PR to last line platinum doublet. Rucaparib at a dose of 600mg twice daily awaits its approval in similar setting with the promising results of the ARIEL3 presented in ESMO 2017.Main toxicity of Olaparib is anemia, nausea and fatigue. (Discontinuation rate 6%)Main toxicity of Niraparib is nausea and haematological (Thrombocytopenia> Anemia>Neutropenia) (Discontinuation rate 15%)Main toxicity of Rucaparib is anemia and elevation of liver enzyme (Discontinuation rate 13%)
Send Enquiry
Read More
Page 1 0.7